Abstract
Evaluate the prevalence of sarcopenia on patients with rheumatoid arthritis (RA), the influence of sarcopenia on disease activity and factors associated with sarcopenia. One hundred and twenty-three patients aged over 18 years with RA based on the 1987 ACR/EULAR classification criteria were enrolled. We performed a whole body DXA scan using a dual-energy X-ray absorptiometry (DXA) scanner lunar prodigy to measure fat mass, lean mass, and bone mass in the whole body and body parts. According to the anthropometric equation by Baumgartner et al., sarcopenia was defined as Relative skeletal mass index (RSMI) <5.5 kg/m2 on women and <7.26 kg/m2 on men. Body mass index (BMI) and waist circumference were measured and patients were classified according to World Health Organization. Disease activity was evaluated by: disease activity score 28 ESR (DAS28 ESR), disease activity score 28 CRP (DAS28 CRP), clinical disease activity index (CDAI), simplify disease activity index (SDAI). We measured functional disability by Health assessment questionnaire (HAQ). History and previous medication use including steroids were also checked, and comorbidities were recorded. We analyzed the relation between disease parameters and sarcopenia with the r of Pearson and Spearman. Factors associated and related to sarcopenia were assessed using multiple regression analysis and t independent test. We included 123 patients (107 women). 49 subjects (39.8%) where suffering from sarcopenia, of which 40 women. Most of the sarcopenic patients were between 41 and 50 years old. Sarcopenia on female subjects was not related to parameters of disease activity evaluated by DAS 28, CDAI and SDAI. Most of the sarcopenic patients had normal BMI and abnormal waist circumference. In simple regression analysis sarcopenia was related to BMI, DAS 28 ESR, bone erosion, waist circumference and HAQ. In multiple regression analysis, sarcopenia was positively related to an increase cardiometabolic risk [p = 0.025, OR 0.176, CI (0.038–0.980)], normal BMI [p = 0.004, OR 12.3, CI (2.27–67.6)], over fat BMI [p = 0.004, OR 12.3, CI (2.27–67.6)] and bone erosion [p = 0.012, OR 0.057 CI (0.006–0.532)]. No statistical difference was found according to disease duration and steroids use between sarcopenic and non sarcopenic patients. Sarcopenia is prevalent and related to age, bone erosion, normal/over fat BMI and high cardiometabolic risk according to waist circumference but not with disease activity.
Similar content being viewed by others
References
Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990–991
Morley JE, Perry HM (2000) Androgen deficiency in aging men: role of testosterone replacement therapy. J Lab Clin Med 135:370–378
Roubenoff R, Rall RC (2004) Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions. Rheumatology 43:1219–1223
Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379–2386
Dao HH, Do QT, Sakamoto J (2011) Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis. Rheumatology (Oxford) 50:1250–1258
El Maghraoui A, Sadni S, Rezqi A, Bezza A, Achemlal L, Mounach H (2015) Does rheumatoid cachexia predispose patients with rheumatoid arthritis to osteoporosis and vertebral fractures? J Rheumatol 42:1556–1562
Giles JT, Bartlett SJ, Andersen RE, Fontaine KR, Barthon JM (2008) Association of body composition with disability in rheumatoid arthritis: impact of appendicular fat and lean tissue mass. Arthitis Rheum 59:1407–1415.
Klein S, Allison DB, Heymsfield SB, Kelley DE, Leibel RL, Nonas C, Kahn R (2007) Waist circumference and cardiometabolic risk: a consensus statement from Shaping America’s Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Am J Clin Nutr 85(5):1197–1202
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, Garry PJ, Lindeman RD (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763
Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, Tylavsky FA, Newman AB (2007) Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 55:769–774
Walsh MC, Hunter GR, Livingstone MB (2006) Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 17:61–67
Doğan SC, Hizmetli S, Hayta E, Kaptanoğlu E, Erselcan T, Güler E (2015) Sarcopenia in women with rheumatoid arthritis. Eur J Rheum:0038.
Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59:807–815
Janssen I, Baumgartner RN, Ross R, Rosenberg IH, Roubenoff R (2004) Skeletal muscle cutpoints as associated with elevated physical disability risk in older men and women. Am J Epidemiol 159:413–421
Visser M, Pahor M, Taaffe DR, Goodpaster BH, Simonsick EM, Newman AB (2002) Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci 57:326–332
Schaap LA, Pluijm SM, Deeg DJ, Visser M (2006) Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med 119(526):9–17
Cesari M, Kritchevsky SB, Baumgartner RN, Atkinson HH, Penninx BW, Lenchik L et al (2005) Sarcopenia, obesity, and inflammation–results from the trial of angiotensin converting enzyme inhibition and novel cardiovascular risk factors study. Am J Clin Nutr 82:428–434
Gallagher D, Ruts E, Visser M, Heshka S, Baumgartner RN, Wang J et al (2000) Weight stability masks sarcopenia in elderly men and women. Am J Physiol Endocrinol Metab 279:E366–E375
Meune C, Touze E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology 48:1309–1313
Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121:S9–S14
Chin SO, Rhee SY, Chon S, Hwang Y-C, Jeong I-K et al (2013) Sarcopenia is independently associated with cardiovascular disease in older korean adults: The Korea National Health and Nutrition Examination Survey (KNHANES) from 2009. PLoS One 8(3):e60119. doi:10.1371/journal.pone
Sanada K, Miyachi M, Tanimoto M, Yamamoto K, Murakami H et al (2010) A cross-sectional study of sarcopenia in Japanese men and women: reference values and association with cardiovascular risk factors. Eur J Appl Physiol 110:57–65
Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P et al (2003) Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil 24:113–119
Pedersen BK (2010) Muscle-to-fat interaction: a two-way street? J Physiol 588(Pt 1):21
Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50:3450–3457
Escalante A, Haas RW, del Rincon I (2005) Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 165:1624–1629
Masuko K (2014) Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis. Front Nutr 1:20
Blanchi G, Rossi V, Muscari A, Magalotti D, Zoli M (2008) Physical activity is negatively associated with the metabolic syndrome in the elderly. Q J Med 101(713):21
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared no conflicts of interest.
Rights and permissions
About this article
Cite this article
Ngeuleu, A., Allali, F., Medrare, L. et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int 37, 1015–1020 (2017). https://doi.org/10.1007/s00296-017-3665-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-017-3665-x